Application of compartmental modeling to an examination of in vitro intestinal permeability data: Assessing the impact of tissue uptake, P-glycoprotein, and CYP3A

Drug Metabolism and Disposition

Volumn 31, Issue 9, 2003, Pages 1151-1160

  Johnson, Brendan M ^a   Charman, William N ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DRUG METABOLITE; GLYCOPROTEIN P; KETOCONAZOLE; MIDAZOLAM; NORVERAPAMIL; VALSPODAR; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE CELL; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT; CYCLOSPORINS; CYTOCHROME P-450 CYP3A; INTESTINAL ABSORPTION; JEJUNUM; KETOCONAZOLE; MALE; MIDAZOLAM; MODELS, BIOLOGICAL; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VERAPAMIL;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0041856526     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.9.1151     Document Type: Article

References (37)

1. Benet LZ and Cummins CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50:S3-S11.
2. Boxenbaum HG, Riegelman S, and Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2:123-148.
3. Chung SM, Park EJ, Swanson SM, Wu TC, and Chiou WL (2001) Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model. Pharm Res (NY) 18:544-547.
4. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
5. Cummins CL, Mangravite LM, and Benet LZ (2001) Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1 and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res (NY) 18:1102-1109.
6. Dresser MJ, Leabman MK, and Giacomini KM (2001) Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90:397-421.
7. Fromm MF, Busse D, Kroemer HK, and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
8. Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, and Thakker DR (1996) CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 24:344-349.
9. Hashimoto Y, Sasa H, Shimomura M, and Inui K (1998) Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res (NY) 15:1609-1613.
10. Hendrikse NH, Schinkel AH, de Vries EGE, Fluks E, van der Graaf WTA, Willemsen ATM, Vaalburg W, and Franssen EJF (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
11. Hochman JH, Chiba M, Nishime J, Yamazaki M, and Lin JH (2000) Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 292:310-318.
12. Ito K, Kusuhara H, and Sugiyama Y (1999) Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Phann Res (NY) 16:225-231.
13. Johnson BM, Charman WN, and Porter CJH (2001) The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J Pharm Pharmacol 53:1611-1619.
14. Johnson BM, Charman WN, and Porter CJH (2002) An in vitro examination of the impact of PEG 400, Pluronic P85 and Vitamin E TPGS on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm Sci 4:40.
15. Johnson BM, Chen W, Borchardt RT, Charman WN, and Porter CJH (2003) A kinetic evaluation of the absorption, efflux and metabolism of verapamil veraparnil in the autoperfused rat jejunum. J Pharmacol Exp Ther 305:151-158.
16. Kivistö KT, Kroemer HK, and Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523-530.
17. Kolars JC, Awni WM, Merion RM, and Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
18. Kolars JC, Schmiedlin-Ren P, Dobbins WO, Schuetz J, Wrighton SA. and Watkins PB (1992) Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186-1198.
19. Landaw EM and DiStefano JJ III (1984) Multiexponential, multicompartmental and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 246:R665-R677.
20. 4 and reduced glutathione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 275:795-803.
21. Makhey VD, Guo AL, Norris DA, Hu PD, Yan JS, and Sinko PJ (1998) Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res (NY) 15:1160-1167.
22. Martin A (1993) Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. Lippincott Williams & Wilkins, Baltimore.
23. Polli JW, Wring SA, Humphreys JE, Huang LY, Morgan JB, Webster LO. and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
24. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, and Gottesman MM (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265:3975-3980.
25. Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoprotein mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res (NY) 12:1304-1310.
26. Sandström R, Knutson TW, Knutson L, Jansson B, and Lennernäs H (1999) The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 48:180-189.
27. Schuetz EG, Beck WT, and Schuetz JD (1996a) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
28. Schuetz EG, Schinkel AH, Relling MV, and Schuetz JD (1996b) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005.
29. Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, and Schinkel AH (2000) Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 57:188-197.
30. Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77:545-590.
31. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
32. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, and Murakami T (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289-294.
33. Tracy TS, Korzekwa KR, Gonzalez FJ, and Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47:545-552.
34. Ungell A-L, Andreasson A, Lundin K, and Utter L (1992) Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat. J Pharm Sci 81:640-645.
35. 7]verapamil and metabolites in biological fluids by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Appl 738:137-147
36. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
37. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.